West China Hospital, Sichuan University
West China Hospital, Sichuan University
Chengdu, Sichuan, China41 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors | Advanced Cancer | Active, not recruiting | Phase 1 / Phase 2 | 2026-09-29 | NCT04495296 | |
| Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines | Moderate to Severe Glabellar Lines | Recruiting | Phase 3 | 2026-09-23 | NCT06937944 | |
| Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Phase 3 | 2026-09-17 | NCT07687459 | |
| To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus | Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus | Recruiting | Phase 2 | 2026-09-17 | NCT07447986 | |
| Safety and Efficacy of Ventricular Irrigation for Ventriculitis | Infections, central nervous system disorder, central nervous system infectious disorder, nervous system disorder | Recruiting | Not applicable | 2026-09-10 | NCT06358209 | |
| Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-08-31 | NCT07079475 | |
| A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, esophageal disorder, gastric neoplasm, intestinal disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm, rectal disorder, stomach disorder | Recruiting | Phase 1 | 2026-08-27 | NCT05262491 | |
| AK117 (Anti-CD47 mAb) Plus Cetuximab or AK104 (Anti-PD-1/CTLA-4 bsAb) as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Active, not recruiting | Phase 2 | 2026-08-19 | NCT06508606 | |
| Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Not yet recruiting | Not stated | 2026-08-18 | NCT07769658 | |
| Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of TJ0113 Capsules in Patients With Early-Onset Parkinson's Disease | Parkinson disease, autosomal recessive early-onset Parkinson disease 6, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Not yet recruiting | Phase 3 | 2026-08-12 | NCT07741045 | |
| Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer | Gastric / Gastroesophageal Junction Adenocarcinoma; MSI-H Cancer | Recruiting | Phase 2 | 2026-08-05 | NCT07127822 | |
| A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma | Neoplasms by Histologic Type, Neoplasms, Adnexal and Skin Appendage, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasm, sebaceous adenocarcinoma | Not yet recruiting | Phase 2 | 2026-08-03 | NCT07740993 | |
| A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Recruiting | Phase 1 / Phase 2 | 2026-07-29 | NCT07327229 | |
| A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy. | Pulmonary Arterial Hypertension PAH | Recruiting | Phase 1 / Phase 2 | 2026-07-22 | NCT07593027 | |
| Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, essential thrombocythemia, hematologic disorder, hemorrhagic disease, thrombocytosis disease | Active, not recruiting | Phase 3 | 2026-07-22 | NCT04285086 | |
| A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bile duct disorder, biliary tract disorder, cholestasis, cirrhosis of liver, intrahepatic cholestasis, liver disorder, primary biliary cholangitis | Recruiting | Phase 3 | 2026-07-08 | NCT07282353 | |
| Clinical Study of MSH2-/- Tumor Cell Vaccines for Advanced pMMR Colorectal Cancer Patients | pMMR/MSS Advanced Colorectal Cancer | Recruiting | Phase 1 | 2026-06-30 | NCT07510308 | |
| Compassionate Administration of ZVS101e for Extended Treatment | Bietti crystalline corneoretinal dystrophy | Enrolling by invitation | Not applicable | 2026-06-17 | NCT07307469 | |
| Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy | Bietti crystalline corneoretinal dystrophy | Active, not recruiting | Phase 1 / Phase 2 | 2026-06-17 | NCT05832684 | |
| Radiotherapy After Prostatectomy for Node Positive Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-06-16 | NCT07477626 | |
| Evaluation of the Safety and Effectiveness of CHORDS® Cerebral Protection System During TAVR: DUET Trial | brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Not applicable | 2026-06-15 | NCT07648693 | |
| Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation | Arrhythmias, Cardiac, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrial fibrillation, cardiovascular disorder, heart disorder | Recruiting | Early phase 1 | 2026-06-04 | NCT06615596 | |
| Sapien 3 Transcatheter Aortic Valve Replacement in Young Aortic Valve Stenosis Patients From China | Bicuspid Aortic Valve Disease, Cardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ventricular Outflow Obstruction, aortic valve disorder, aortic valve stenosis, cardiovascular disorder, congenital heart disease, heart disorder, heart valve disorder | Recruiting | Not stated | 2026-05-27 | NCT06830499 | |
| LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB | Arrhythmias, Cardiac, Cardiac Conduction System Disease, Left Bundle-Branch Block, Pathologic Processes, Pathological Conditions, Signs and Symptoms, atrioventricular dissociation, cardiovascular disorder, heart disorder, heart failure, progressive familial heart block, type 1A | Active, not recruiting | Not applicable | 2026-05-14 | NCT05572957 | |
| JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC | Advanced Solid Tumor | Not yet recruiting | Phase 1 | 2026-05-13 | NCT07582822 |